Patent ID: 8067022

Claim:
A method for reducing restenosis following a vascular surgical procedure, the method comprising: locally administering to a human a biocompatible, non-biodegradable sustained release dosage form comprising a cytostatic amount of a therapeutic agent dispersed in a polymer matrix, wherein said cytostatic amount of said therapeutic agent inhibits a vascular smooth muscle cell activity without killing the cell, and wherein said therapeutic agent is a TGF-beta production or activation stimulator, TGF-beta, tamoxifen, a nuclear enzyme DNA topoisomerase II inhibitor, a DNA polymerase inhibitor, an RNA polymerase inhibitor, an adenyl guanyl cyclase inhibitor, a superoxide dismutase inhibitor, a terminal deoxynucleotidyl-transferase, a reverse transcriptase, lovastatin, vinblastin, cytochalasins, taxol, taxotere, trichothecene, Pseudomonas exotoxin, a chemotactic factor inhibitor, a chemotactic factor receptor inhibitor, an intracellular cytoskeletal protein inhibitor, a caffeic acid derivative, nilvadipine, a steroid hormone, sphingosine, somatostatin, or N-ethylmaleimide.